Peripheral Neuropathy Market By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies) - Growth, Future Prospects And Competitive Analysis 2017 – 2025
General population studies have reported that 7 to 8% adults currently have chronic neuropathic pain, where the reported incidence is of 8 cases per 1,000 individuals per year. In the U.K. alone, 26% individuals with diabetes experience peripheral neuropathic pain. Globally, this figure translates to approximately 50 million individuals, which will further increase as is anticipated that the prevalence of diabetes will grow to an estimated 4.4% by 2030. Anticonvulsant pregabalin (Lyrica, Pfizer) is among the most widely spread drug for neuropathic pain. Drug manufacturers and developers are thus required to demonstrate improved efficacy to patients while simultaneously report cost-benefit to insurers and regulatory bodies. In terms of market competition, the existing brands are being continually expanded across geographies. Commercialization of pipeline entities into the market will somewhat offset generic erosion
The report titled “Peripheral Neuropathy Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2017 to 2025. The said research study covers in-depth analysis of multiple market segments based on type of treatment and different geographies. The drug types studied for analyzing the overall global peripheral neuropathy market are majorly segmented into pharmacological therapies and non-pharmacological therapies. Pharmacological therapies includes pain reliever, anti-seizure medication, antidepressants. Non Pharmacological therapies transcutaneous electrical nerve stimulation, plasma exchange and intravenous immune globulin and others (physical therapy and surgery).
Geographically, the global peripheral neuropathy market is studied for the following regional markets:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Mexico
- Brazil
- Rest of LATAM
- Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global peripheral neuropathy market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global peripheral neuropathy market. This report concludes with company profiles section that highlights major information about the key players engaged in global peripheral neuropathy market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.
Based on the type of treatment, the global peripheral neuropathy market is segmented as follows:
- Pharmacological Therapies
- Pain Relievers
- Tramadol
- Oxycodone
- Cylcooxgenase Inhibitors
- Corticosteroid
- Anti-seizure medications
- Gabapentin
- Pregabalin
- Antidepressants
- Amitriptyline
- Doxepin
- Nortriptyline
- Duloxetine
- Venlafaxine
- Pain Relievers
- Non-Pharmacological Therapies
- Transcutaneous electrical nerve stimulation
- Plasma exchange and intravenous immune globulin
- Others(Physical Therapy and Surgery)
Pharmacological therapies most commonly used and dominates the peripheral neuropathy market, while non-pharmacological therapies are used along with other treatment options. Anti-seizures medications occupies maximum share in peripheral market around 41% in 2016, followed by antidepressants and pain killers. Anti-seizures medication include Gabapentin and Pregabalin, that are used as first line of treatment, with Pregabalin occupying major share. Among antidepressants, Amitriptyline is widely recommended for neuropathic pain and thus dominates the peripheral neuropathy antidepressant market.
For the purpose of this study, the global gastrointestinal agents market is geographically categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
At present, North America was observed as the largest market for peripheral neuropathy. The rising geriatric population, growing incidences of diabetes in the region is the prime factor driving the North America peripheral neuropathy market. U.S. held the largest share in North America due to factors such as developed healthcare infrastructure, major pharmaceutical giants based in the country, high research trials on peripheral neuropathy in the country and high prices of the medication generating high revenue. Asia Pacific would exhibit the fastest growth rate in the Global Peripheral Neuropathy market due to aging population, increasing health awareness and high prevalence of the diabetes, cancer and HIV/AIDS.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.2.1 Phase I – Secondary Research
1.2.2 Phase II – Primary Research
1.2.3 Phase III – Expert Panel Review
1.2.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Peripheral Neuropathy Market Portraiture
2.2 Global Peripheral Neuropathy Market Revenue, by Treatment, 2016 Vs 2025, (Value %)
2.3 Global Peripheral Neuropathy Market Revenue, by Geography, 2016, (US$ Million)
Chapter 3 Global Peripheral Neuropathy Market Analysis
3.1 Peripheral Neuropathy Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Growing prevalence of diabetes and cancer
3.2.1.2 Growing preference for non-pharmacological modalities
3.2.2 Challenges
3.2.2.1 Challenge of Developing New Pain Medications for Neuropathic Pain
3.2.2.2 High treatment rate as against low satisfaction indicate gap in treatment
3.2.3 Opportunities
3.2.3.1 Development of drugs with selective targeting of ion channels
3.3 Attractive Investment Proposition
3.4 Market Positioning of Key Players in Global Peripheral Neuropathy Market
Chapter 4 Global Peripheral Neuropathy Market, by Treatment Type
4.1 Overview
4.2 Pharmacological Therapies
4.2.1 Pain Relievers
4.2.1.1 Tramadol
4.2.1.2 Oxycodone
4.2.1.3 Cylcooxgenase Inhibitors
4.2.1.4 Corticosteroid
4.2.2 Anti-seizure medications
4.2.2.1 Gabapentin
4.2.2.2 Pregabalin
4.2.3 Antidepressants
4.2.3.1 Amitriptyline
4.2.3.2 Doxepin
4.2.3.3 Nortriptyline
4.2.3.4 Duloxetine
4.2.3.5 Venlafaxine
4.3 Non-Pharmacological Therapies
4.3.1 Transcutaneous electrical nerve stimulation
4.3.2 Plasma exchange and intravenous immune globulin
4.3.3 Others(Physical Therapy and Surgery)
Chapter 5 Global Peripheral Neuropathy Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.6 Middle East and Africa (UAE, Saudi Arabia and South Africa)
Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Bristol Myers Squibb
6.3 Cipla Limited
6.4 Eli Lilly and Company
6.5 GlaxoSmithKline plc.
6.6 Lupin Limited
6.7 Merck and Co. Inc.
6.8 Novartis
6.9 Pfizer Inc.
6.10 Dr. Reddy's Laboratories
TABLE 1 Global Peripheral Neuropathy Market, by Treatment Type, 2015 – 2025 (US$ Mn)
TABLE 2 Pharmacological Therapies Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 3 Pain Relievers Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 4 Anti-seizure Medications Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 5 Antidepressant Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 6 Non- Pharmacological Therapies Global Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
TABLE 7 Global Peripheral Neuropathy Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 8 North America Peripheral Neuropathy Market , by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Europe Peripheral Neuropathy Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Asia-Pacific Peripheral Neuropathy Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Abbott Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 12 Bristol Myers Squibb: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 Cipla Limited.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 14 Eli Lilly and Company: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 16 Lupin Limited.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 Merck and Co. Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Novartis: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Pfizer Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Dr. Reddy's Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
FIG. 1 Global Peripheral Neuropathy Market: Research Methodology
FIG. 2 Global Peripheral Neuropathy Market Revenue, by Treatment, 2016 Vs 2025 (Value %)
FIG. 3 Global Peripheral Neuropathy Market Revenue, by Geography, 2016 (US$ Million)
FIG. 4 Attractive Investment Proposition: Global Peripheral Neuropathy Market, by Region
FIG. 5 Market Positioning of Key Players: Global Peripheral Neuropathy Market
FIG. 6 Tramadol Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 7 Oxycodone Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 8 Cylcooxgenase Inhibitors Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 9 Corticosteroid Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 10 Gabapentin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 11 Pregabalin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 12 Amitriptyline Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 13 Doxepin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 14 Nortriptyline Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 15 Duloxetine Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 16 Venlafaxine Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 17 Transcutaneous Electrical Nerve Stimulation Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 18 Plasma Exchange and Intravenous Immune Globulin Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 19 Others (Physical Therapy and Surgery) Global Peripheral Neuropathy Market, 2015-2025 (US$ Mn)
FIG. 20 Latin America Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
FIG. 21 Middle East & Africa Peripheral Neuropathy Market, 2015 – 2025 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)